PROJECT 12. Protocal Review

项目 12. 协议审查

• 批准号: 8740623
• 负责人: John Hayslip
• 金额: $ 5.31万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-07-08 至 2018-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8740623
• 关键词: Area; Basic Science; Behavioral Sciences; Cancer Center; Cancer Center Support Grant; Charge; Clinical; Clinical Data; Clinical Research; Clinical Sciences; Clinical Trials; Colorectal Cancer; Development; Documentation; England; Ensure; Equilibrium; Future; Incidence; Instruction; Kentucky; Lead; Malignant Neoplasms; Malignant neoplasm of lung; Medical center; Monitor; Patient Care; Patients; Population Heterogeneity; Population Sciences; Poverty; Process; Protocols documentation; Research Personnel; Resource Sharing; Resources; Risk Behaviors; Services; Smoking; System; Therapeutic Human Experimentation; Translations; United States; Universities; anticancer research; authority; data management; health disparity; novel; operation; research study; screening; translational clinical trial

The Markey Cancer Center (MCC) Protocol Review and Monitoring System (PRMS) provides thorough review of clinical trials for scientific validity, feasibility and prioritization within the clinical trials portfolio and monitoring of scientific progress. The PRMS must approve all interventional cancer research prior to study initiation and has the authority to recommend closure of trials for lack of scientific progress or patient accrual. The PRMS provides a framework which aims to balance appropriate resource utilization while maximizing the opportunities for current and future patients with cancer in this region to participate in clinical trials, including the underserved area of Appalachian Kentucky. The development of novel MCC investigator initiated clinical trials and participation in high-priority national trials provide a robust portfolio of therapeutic research studies available to MCC patients.

Markey癌症中心（MCC）方案审查和监测系统（PRMS）提供了对临床试验的科学有效性，可行性和临床试验组合中的优先级以及科学进展监测的全面审查。PRMS必须在研究开始前批准所有干预性癌症研究，并有权建议关闭缺乏科学进展或患者招募的试验。PRMS提供了一个框架，旨在平衡适当的资源利用，同时最大限度地提高该地区当前和未来癌症患者参与临床试验的机会，包括服务不足的阿巴拉契亚肯塔基州。新型MCC研究者发起的临床试验的开发和高优先级国家试验的参与为MCC患者提供了强大的治疗研究组合。